Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice Wegovy beginning to curb appetite within the first one to four weeks of starting treatment, though the degree of suppression builds gradually over months as the dose increases. Semaglutide works on GLP-1 receptors that regulate hunger signals in the brain, so the effect is progressive rather than immediate. These are prescription-only medicines; a prescriber assesses whether they are clinically appropriate for you before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common misconception is that semaglutide works like a light switch. People expect to wake up the morning after their first 0.25mg injection with no interest in food whatsoever. That is not how it works, and understanding why makes the real timeline much easier to manage.
The 0.25mg starting dose is a tolerability step. Its job is to let your body adjust to the medicine, not to deliver the full appetite effect. Most people at this stage notice a modest reduction in how hungry they feel between meals, or find they feel full a little sooner than usual. Some notice nothing for the first week or two. Both responses are normal.
The hunger-regulation pathway that semaglutide acts on involves GLP-1 receptors in the hypothalamus and gut. Slowing gastric emptying and signalling fullness to the brain are both part of the picture. Those effects are real from the first dose, but they become meaningfully stronger as the dose increases through the titration schedule. The Wegovy treatment overview covers how the titration schedule is structured and what each stage involves.
The licensed titration pathway runs from 0.25mg up through 0.5mg, 1.0mg and 1.7mg to the 2.4mg maintenance dose, with roughly four weeks at each level. For most people, how quickly semaglutide reduces appetite becomes clearer somewhere in the 0.5mg to 1.0mg range, usually six to twelve weeks in, when suppression grows noticeably stronger. By 1.7mg and 2.4mg, the effect is at its most pronounced for the majority of patients.
This matters practically. If you start Wegovy expecting a dramatic change in the first fortnight and feel little, the temptation is to conclude it is not working. For most people, the medicine is working exactly as it should, settling your system before the dose that actually changes your appetite arrives a few weeks later. The full breakdown of how long Wegovy takes to work covers weight-loss timelines as well as appetite, if you want the broader picture.
One practical note: many people find it useful to do their weekly injection on the same day each week (Sunday evening, say) so the rhythm becomes automatic before the full effects are felt. That consistency matters more than it might seem.
The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults on semaglutide 2.4mg over 68 weeks. Average weight loss was around 15% of body weight. Those results reflect sustained appetite suppression built up over the full titration period, not a single-dose effect.
Appetite suppression from semaglutide varies between people, and that variation is genuine rather than a sign that treatment has failed. Factors that influence how quickly and strongly the effect is felt include metabolic rate, the composition of meals (fat and protein slow gastric emptying further, amplifying satiety), and how sensitive an individual's GLP-1 receptors are.
Gastrointestinal side effects (nausea, early fullness, mild reflux) can make appetite suppression feel more pronounced in the early weeks simply because eating feels uncomfortable. This is not the same as the therapeutic effect. As the GI symptoms settle, usually over a few weeks, the appetite effect that remains is the actual pharmacological one. The NHS semaglutide medicines page has a plain-English summary of what to expect and when to seek help.
If you are thinking about what happens to appetite after stopping Wegovy, that is a separate and important question, appetite does tend to return once treatment stops, which is why the medicine is used as part of an ongoing plan.
Questions about your own response (whether your appetite suppression feels too weak, too strong, or accompanied by symptoms that worry you) belong with your prescriber. Our team is available seven days a week for aftercare queries once you are on treatment.
Wegovy is a prescription-only medicine, so the route to starting it always involves a clinical assessment. On the NHS, access is through specialist weight management services and waiting times can be substantial. How quickly semaglutide suppresses appetite is a separate question from how quickly you can access treatment, for many people, the private route removes that second waiting period entirely.
If you are weighing up the cost, the Wegovy pricing page explains what an all-in private prescription includes and how to read a headline price honestly. The right question for a prescription medicine is never just what it costs, it is what the price actually covers.
For a fuller comparison of semaglutide and tirzepatide on appetite and weight outcomes, the weight-loss treatment overview sets out the evidence side by side.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.